-
CP-673451: Selective PDGFRα/β Assay Guide
2026-08-22
CP-673451 is a practical tool for separating PDGFR-driven signaling from broader RTK activity in cancer research. This workflow connects pathway engagement, angiogenesis inhibition assays, ATRX-stratified glioma experiments, and tumor growth suppression in xenograft models while emphasizing controls and troubleshooting.
-
G-1: Selective GPR30 Agonist Workflows
2026-08-21
G-1 enables controlled interrogation of rapid GPR30 signaling in immune, cardiovascular, and oncology assays. This practical guide connects receptor-selective pharmacology with reproducible cell workflows, heart failure model design, migration assays, and troubleshooting strategies.
-
Anlotinib hydrochloride: Angiogenesis Workflow
2026-08-20
Build a reproducible anti-angiogenic workflow around receptor phosphorylation, endothelial cell migration, tube formation, and viability controls. The approach connects concentration-resolved bench assays with translational observations in desmoplastic small round cell tumors while keeping clinical interpretation appropriately cautious.
-
CBD, Orofacial Pain, and Affective Recovery
2026-08-20
A 2026 Brain Research Bulletin study shows that cannabidiol (CBD) can reduce both inflammatory orofacial pain and associated anxiety-, depression-, and cognition-related deficits in mice. Its main contribution is a mechanistic separation of peripheral CB2-linked anti-inflammatory effects from central CB1-associated modulation of trigeminal, limbic, and serotonergic circuits.
-
Crizotinib Hydrochloride in ALK Research
2026-08-19
Crizotinib hydrochloride is an ATP-competitive ALK kinase inhibitor that also targets c-Met and ROS1 for mechanism-driven cancer biology research. Its phosphorylation effects and solvent-specific handling data support controlled studies in cell systems and patient-derived models, but the product is not a clinical or diagnostic material.
-
SMAD3 Inhibition Lowers ADAMTS-5 in Early OA
2026-08-19
Xiang et al. identify a regulatory connection between SMAD3, miRNA-140, and ADAMTS-5 during early osteoarthritis. Their cell and rat experiments show that inhibiting SMAD3 increases miRNA-140 and reduces the cartilage-degrading enzyme ADAMTS-5, supporting a mechanistic framework for studying early extracellular-matrix loss.
-
Hydroxychloroquine Sulfate Workflow Guide
2026-08-18
Hydroxychloroquine Sulfate (SKU B4874) provides a water-compatible research reagent for examining autophagy pathway modulation and TLR7/9-dependent immune signaling in autoimmune disease research. It is suited to short-term aqueous workflows, but not to protocols requiring DMSO or ethanol solubility or long-term storage of prepared solutions.
-
EMD638683: A Mechanism-First SGK1 Inhibitor Guide
2026-08-18
EMD638683 is a selective SGK1 inhibitor for dissecting kinase-dependent sodium-channel signaling, endothelial stiffening, and tumor-cell stress. This guide focuses on causal assay design, target-engagement controls, and how to interpret vascular and oncology findings without overextending the evidence.
-
PD 173074 in LUAD Functional Assay Design
2026-08-17
PD 173074 can do more than inhibit FGFR1: it can help researchers functionally test drug-response patterns emerging from CENPO-centered lung adenocarcinoma studies. This article presents an assay strategy that connects FGFR signaling pathway inhibition with rigorous interpretation of genomic risk models.
-
GDC-0994: ERK1/2 Inhibition Beyond Oncology
2026-08-17
GDC-0994 offers a practical way to interrogate ERK1/2 as a convergent signaling node in both oncogenic tumors and estrogen-associated cholestatic injury. This translational perspective connects pathway biology, experimental design, target-engagement strategy, and the limitations that must be addressed before preclinical observations can inform therapeutic development.
-
Merbromin: Practical Fluorescence Assay Workflows
2026-08-16
Merbromin combines protein-binding fluorescence, enzyme inhibition, antimicrobial activity, and experimental tissue-marking utility in one research compound. This guide translates those properties into reproducible workflows, controls, troubleshooting steps, and evidence-aware application choices.
-
Catalpol, SDF-1α/CXCR4, and Ischemic Stroke
2026-08-15
This study identifies the SDF-1α/CXCR4 axis as a mechanistic link between Catalpol treatment, neural stem cell responses, and vascular remodeling after permanent cerebral ischemia. By combining a rat permanent middle cerebral artery occlusion model with oxygen–glucose deprivation assays, the authors provide preclinical evidence that Catalpol supports both neurogenesis and angiogenesis rather than targeting neuronal survival alone.
-
Halazone and Sodium Current Inactivation in Frog Nerves
2026-08-14
The reference study showed that Halazone and hypochlorous acid strongly disrupt sodium-current inactivation in voltage-clamped frog nerve fibers, while several other oxidants produce different effects. Its comparative reagent design argues against a uniquely essential methionine residue and instead supports membrane-lipid modification as a tentative explanation for altered channel kinetics.
-
Targeted SPP1 Inhibition Reprograms Tumor Myeloid Cells
2026-08-14
The reference study identifies a phenotypic small-molecule screening and nanomedicine strategy for reducing SPP1 expression in tumor-associated macrophages. Its lead modulator, CANDI460, lowered SPP1 in vitro and in vivo and reduced tumor burden across murine models, providing a complementary approach to broad macrophage depletion.
-
AAL-993: From Receptor Potency to Assay Design
2026-08-13
AAL-993 is a selective VEGF receptor inhibitor for dissecting angiogenic signaling, endothelial responses, and tumor–vascular interactions. This guide translates its kinase profile and the SFI glioma network-pharmacology study into practical assay and interpretation strategies.